Urine biomarkers can predict prostate cancer and PI-RADS score prior to biopsy.

Pavlovic, Blaz; Bräutigam, Konstantin; Dartiguenave, Florence; Martel, Paul; Rakauskas, Arnas; Cesson, Valérie; Veit, Markus; Oechslin, Pascal; Gu, Alexander; Hermanns, Thomas; Saba, Karim; Poyet, Cédric; Hötker, Andreas M; Rupp, Niels J; Valerio, Massimo; Derré, Laurent; Eberli, Daniel; Banzola, Irina (2024). Urine biomarkers can predict prostate cancer and PI-RADS score prior to biopsy. Scientific Reports, 14(18148) Nature Publishing Group 10.1038/s41598-024-68026-1

[img]
Preview
Text
s41598-024-68026-1.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (4MB) | Preview

Prostate-Specific Antigen (PSA) based screening of prostate cancer (PCa) needs refinement. The aim of this study was the identification of urinary biomarkers to predict the Prostate Imaging-Reporting and Data System (PI-RADS) score and the presence of PCa prior to prostate biopsy. Urine samples from patients with elevated PSA were collected prior to prostate biopsy (cohort = 99). The re-analysis of mass spectrometry data from 45 samples was performed to identify urinary biomarkers to predict the PI-RADS score and the presence of PCa. The most promising candidates, i.e. SPARC-like protein 1 (SPARCL1), Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1), Alpha-1-microglobulin/bikunin precursor (AMBP), keratin 13 (KRT13), cluster of differentiation 99 (CD99) and hornerin (HRNR), were quantified by ELISA and validated in an independent cohort of 54 samples. Various biomarker combinations showed the ability to predict the PI-RADS score (AUC = 0.79). In combination with the PI-RADS score, the biomarkers improve the detection of prostate carcinoma-free men (AUC = 0.89) and of those with clinically significant PCa (AUC = 0.93). We have uncovered the potential of urinary biomarkers for a test that allows a more stringent prioritization of mpMRI use and improves the decision criteria for prostate biopsy, minimizing patient burden by decreasing the number of unnecessary prostate biopsies.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology > Clinical Pathology
04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Bräutigam, Konstantin

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

2045-2322

Publisher:

Nature Publishing Group

Language:

English

Submitter:

Pubmed Import

Date Deposited:

06 Aug 2024 10:26

Last Modified:

06 Aug 2024 10:35

Publisher DOI:

10.1038/s41598-024-68026-1

PubMed ID:

39103428

Uncontrolled Keywords:

Early detection Non-invasive PI-RADS score PSA Prostate biopsy Prostate cancer Prostate specific antigen Screening of prostate cancer Urinary biomarker mpMRI

BORIS DOI:

10.48350/199512

URI:

https://boris.unibe.ch/id/eprint/199512

Actions (login required)

Edit item Edit item
Provide Feedback